cific for C. jejuni antigens and in protection from illness after a second challenge with the same organism [5] . The morbidity associated with Campylobacter infections and the evidence for immune protection against C. jejuni disease are the foundation of ongoing efforts to formulate vaccines against C. jejuni [4] . However, vaccine construction is confounded by the lack of knowledge of virulence mechanisms and the antigenic targets of protective immune responses and by the knowledge that adults who have had Campylobacter infection may develop subsequent enteritis caused by Campylobacter [6] . The serendipitous natural acquisition of C. jejuni infection by a volunteer participant in ongoing studies for whom an archive of plasma and mononuclear cells existed enabled a study of this patient's immune recognition of C. jejuni before, during, and after the current infection.
Case report. A previously healthy 46-year-old man, a US expatriate residing in Egypt, developed fever (temperature, 40ЊC), headache, and myalgia while en route from Cairo to the United States (case day 0). The patient had lived in Egypt for the past 4 years and had not traveled outside of Egypt during the preceding month. Watery diarrhea developed the next morning, and stool frequency peaked on the third day of illness, at 14 watery stools per day. Fever, headache, and myalgia persisted. The patient presented to a local hospital on the third day of illness. Physical examination revealed a temperature of 38.9ЊC, a pulse rate of 109 beats/min, and abdominal tender- On day 6, the laboratory reported the isolation of C. jejuni from a day 3 stool sample. On day 7, treatment was changed to erythromycin (250 mg 4 times a day for 5 days). Results of testing of a second stool sample collected at day 8 and evaluated at the US Naval Medical Research Center were negative for C. jejuni and positive for gross blood; showed WBCs in sheets; and were positive for lactoferrin, through a dilution of 1:1 million by a latex agglutination test (TechLab). Additional blood samples were collected 10, 34, and 120 days after the onset of symptoms.
The isolate (designated "isolate 20-01") was obtained from the hospital. Tests made at the Naval Medical Research Center confirmed that the bacterium was C. jejuni. Gram stain and scanning electron microscopy (see figure 136-1 in Heresi and Cleary [2] ) revealed staining and morphology consistent with a flagellated C. jejuni. Selected tests of phenotypic characteristics showed a pattern consistent with C. jejuni: the isolate grew on Campylobacter blood agar (Remel) and was catalase positive, hippurate positive, nitrate reduction positive, urease negative, and hydrogen sulfide negative; further, it was sensitive to nalidixic acid, resistant to cephalothin, had no growth at 25ЊC, and showed growth at 42ЊC. Silver-stained sodium dodecyl sulfate-PAGE gels revealed a protein profile for 20-01 that was similar to that of reference strain 81-176 (figure 1). The case isolate did not react in the Lior serotyping schema, in which C. jejuni 81-176 yielded a result of type 5 (testing for 120 serotypes was done at the Laboratory Center for Disease Control [Ottawa]), and 20-01 had a slightly higher virulence for BALB/c mice than the well-studied 81-176 isolate [8] .
Immunologic recognition of C. jejuni before onset of symptoms. Table 1 presents patterns of immunologic recognition of isolates 20-01 and 81-176 seen in plasma and mononuclear cells collected 801 and 261 days before onset of the illness currently under discussion. Most serologic procedures were applied to plasma samples collected on day Ϫ801 and on day Ϫ261. Results at the beginning and end of this interval were remarkably similar and have been averaged. Antibodies reacting with C. jejuni 20-01 and 81-176 were found. Immunoblots made on plasma collected at Ϫ261 days showed IgG antibodies that reacted with numerous C. jejuni antigens (figure 2, panel Ϫ261, rows 2 and 3); antigens prepared from isolates 20-01 and 81-176 were similarly recognized. IgA reacted with fewer antigens, but the different C. jejuni isolates were recognized nonetheless.
Tests of mononuclear cell immune recognition of C. jejuni were made on cells obtained at day Ϫ261 (table 1) . The patient did not have antibody-secreting cells (ASCs) that reacted with any of the tested C. jejuni antigens. In contrast, mononuclear cells tested by antigen-driven lymphocyte replication assay showed notable recognition of isolate 81-176, but not 20-01, antigen. The volunteer had humoral and cellular immune recognition of C. jejuni before the current infection.
Responses to C. jejuni infection. Rapid, vigorous, and sustained antibody responses specific to C. jejuni were seen after infection ( figure 3 ). Marked increases in anti-C. jejuni antibodies were present at day 3, most responses peaked at day 10, Western blots were made by loading 12% gels with the above-listed materials; after electrophoresis, they were transferred to nitrocellulose membranes and hybridized with the indicated plasma. Bands were visualized by use of enhanced-chemiluminescence substrate (Amersham) and exposure to x-ray film. Plasma was collected at each interval and stored frozen; samples were concomitantly recovered for use in the experiment [7] . Figure 3 . Humoral immune responses. The frames present the assay procedure, the antigen used, and, for ELISA tests, the Ig isotype. GE, glycine extract antigen [9] ; LPS, lipopolysaccharide; WC, inactivated (formalin-killed) bacterial whole cells. Established methods were used [9, 10] . and all responses persisted through day 120. Antibody responses had both genus and species specificity and a degree of isolate specificity. Responses to isolate 20-01 were somewhat more vigorous, more rapid, or both than responses to 81-176. The antibody response to 81-176 lipopolysaccharide was weak and delayed compared with the other responses, and it lacked an IgA component. Western blot analyses showed rapid and sustained increases in antibodies recognizing multiple C. jejuni components (figure 2). Both the numbers of antigens detected and the density of bands increased by day 3 and peaked at day 10 (IgA) or 34 (IgG). Enhanced IgG recognition persisted at least through day 120, whereas IgA responses waned substantially by day 34. Although the majority of antigens detected were shared between the 2 strains, 20-01 had 2 bands (at 34 and 31.5 kDa) that were unique.
Rapid and vigorous ASC responses specific to C. jejuni were documented (figure 4). Significant increases in C. jejuni-specific ASCs were present at day 3, and IgM responses peaked at this time, whereas IgA and IgG ASC responses peaked at day 10. All responses waned to near undetectable levels by day 34. ASC responses were both genus and isolate specific. The IgA and IgG ASC responses to 81-176 glycine extract antigen were approximately 50% of responses to isolate 20-01 glycine extract antigen.
Lymphocyte replication assays (figure 4) showed a rapid, vigorous, sustained, and specific response to C. jejuni 20-01 antigen. Increased response was seen at day 3, and this persisted at increased levels at least through day 120. In contrast, there was little change in lymphocyte replication response to 81-176 antigen as the result of infection.
Cytokine and C-reactive protein (CRP) responses were rapid (figure 5). With the exception of TNF-a levels, which were never elevated, plasma inflammatory cytokines and CRP levels were increased on day 3. IL-8 levels peaked at day 3 and IL-1 and CRP levels on day 10. In contrast, regulatory cytokines (IL-6 and IFN-g) were not detected at day 3 but were present in high concentrations at day 10.
Discussion. This case of C. jejuni enteritis occurred in a man whose preinfection immunologic markers denoted previous experience with Campylobacter. The occurrence of disease shows that this immunity was not protective. Because there was no evidence of immune deficit before or after this illness, it is likely that the illness resulted from infection either with a Campylobacter capable of defeating the existing immune mechanisms or with a C. jejuni that differed in antigenic targets of protective immune responses from C. jejuni previously encountered by the patient. Direct evidence was obtained that the causative bacterium was antigenically special. Some notable differences were seen: in essentially all immunologic assays, responses to 20-01 were more rapid or greater than responses to 81-176; plasma collected after infection uniquely recognized 31.5-and 34-kDa proteins in 20-01; and 20-01 was untypeable by the Lior serotyping system. The 31.5-kDa protein is consistent with the known mass of PEB4 [7] , a surface component that is known to vary markedly among Campylobacter isolates. The identification of the 34-kDa unique protein is not known. On the other hand, numerous antigens were shared between isolates 20-01 and 81-176, and immune recognition of some of these predated the current infection. Notable in this regard were strong antibody responses to an ∼60-kDa protein that may correspond to flagellin [12] . This protein was similarly recognized in 20-01 and 81-176 antigen preparations and was strongly recognized by plasma collected before the present infection. The significance of this observation to flagellin-based vaccine development deserves consideration.
Western blot analyses made as part of this study differ from those reported previously; an increased number of antigens and an increased density of bands were detected in plasma collected before infection. The pattern of antigens detected by Western blots in after-infection plasma is, in general, similar to those previously reported [13] [14] [15] [16] . It is possible that the 20-01-specific 31.5-and 34-kDa proteins are similar to patient isolate-specific proteins of approximately these masses visualized by Mills and Bradbury [16] in serum samples from a laboratory worker infected with a known C. jejuni strain.
It is notable that the subject of this study lacked lymphocyte response to isolate 20-01 before the present infection, yet developed this as a result of the infection. In contrast, the man had lymphocyte response to 81-176 before and after infection, and lymphocyte response to 81-176 was not boosted by 20-01 infection. Because the antigen used to elicit these responses preferentially detects immune recognition of bacterial surface components [11] , the results indicate that 20-01 is antigenically different from 81-176. This suggests that cellular immune response to a C. jejuni surface component may correlate with protection from disease.
It was also notable that acute and resolved infections were clearly distinguishable by the absence of IFN-g and IL-6 during acute infection; it would have been difficult to make a diagnosis based on testing for antibodies in acute-phase and convalescent-phase plasma samples if preinfection plasma had not been available. The rate of the antibody response was so rapid that the plasma collected at day 3 (day of presentation to the hospital), during the acute phase, already had high levels of antibodies, and in only 1 instance did a later plasma sample have a titer 14-fold higher than the day 3 level. The ASC procedure was best for making an immunologic diagnosis of infection, a finding consistent with studies of other enteric bacterial pathogens [17] .
C. jejuni strain 20-01 was capable of causing illness in a man in the face of established immune recognition of C. jejuni; the strain differs antigenically from 81-176, a strain that was used in previous and ongoing volunteer studies. The 20-01 strain may be useful in studies to resolve protective immune responses and mechanisms of pathogenesis.
